Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers – a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale-Reference-Cited by-同舟云学术

Investigating the lowest threshold of vascular benefits from LDL cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers – a mechanistic physiological study (INTENSITY-LOW): protocol and study rationale

Published:2019-01-01 Issue:1 Volume:8 Page:167-174
ISSN:2155-6660
Container-title:Journal of Drug Assessment
language:en
Short-container-title:Journal of Drug Assessment

Author:

Kostapanos Michael S.¹²,Cacciottolo Paul J.¹,Hubsch Annette¹,Pavey Holly³^ORCID,Hurlock James³,Maki-Petaja Kaisa¹,Wilkinson Ian B.¹³,Cheriyan Joseph¹³

Affiliation:

1. Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, UK;

2. Lipid Clinic, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK;

3. Cardiovascular Trials Office, Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/21556660.2019.1677673

Reference26 articles.

1. Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions

2. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

3. Endothelial Function in Resistance and Conduit Arteries and 5-Year Risk of Cardiovascular Disease

4. Acute Systemic Inflammation Impairs Endothelium-Dependent Dilatation in Humans

5. Cardiovascular risk factors and endothelial dysfunction

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study;BMJ Open;2021-04